Nyxoah (NYXH) FDA Approvals $2.95 -0.03 (-1.14%) As of 12:08 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Nyxoah's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Nyxoah (NYXH). Over the past two years, Nyxoah has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Genio. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Genio FDA Regulatory Events Genio is a drug developed by Nyxoah for the following indication: For the Treatment of Obstructive Sleep Apnea. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. FDA approved - August 8,2025Fda Approved Drug: GenioAnnounced Date: August 8, 2025Indication: For the Treatment of Obstructive Sleep ApneaAnnouncementNyxoah SA announced that the U.S. Food and Drug Administration (FDA) has approved the Genio system for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65.AI SummaryNyxoah SA announced that the U.S. Food and Drug Administration has approved the Genio system for treating obstructive sleep apnea in patients with an Apnea-Hypopnea Index (AHI) between 15 and 65. Genio uses bilateral hypoglossal nerve stimulation with a leadless implant, a non-implanted battery solution, and a full-body 1.5T/3T MRI-compatible wearable controller. The wearable component powers, controls, and can be fully upgraded for software and battery without surgery. In the DREAM pivotal trial, Genio met key safety and efficacy endpoints. It achieved a 63.5% AHI responder rate, a 71.3% oxygen desaturation responder rate, and a 70.8% median AHI reduction. Moreover, 82% of participants lowered their AHI to below 15. Genio proved effective in all sleeping positions, cutting AHI by 66.6% when patients lay on their back and by 71% in other positions. Olivier Taelman, Nyxoah’s CEO, said this approval marks a milestone in bringing innovative, simple sleep therapy to U.S. patients with moderate to severe OSA.Read Announcement Nyxoah FDA Events - Frequently Asked Questions Has Nyxoah received FDA approval? As of now, Nyxoah (NYXH) has not received any FDA approvals for its therapy in the last two years. What drugs has Nyxoah submitted to the FDA? In the past two years, Nyxoah (NYXH) has reported FDA regulatory activity for Genio. What is the most recent FDA event for Nyxoah? The most recent FDA-related event for Nyxoah occurred on August 8, 2025, involving Genio. The update was categorized as "FDA approved," with the company reporting: "Nyxoah SA announced that the U.S. Food and Drug Administration (FDA) has approved the Genio system for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65." What conditions do Nyxoah's current drugs treat? Currently, Nyxoah has one therapy (Genio) targeting the following condition: For the Treatment of Obstructive Sleep Apnea. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Candel Therapeutics FDA EventsCelcuity FDA EventsCingulate FDA EventsCo-Diagnostics FDA EventsCumberland Pharmaceuticals FDA EventsEvogene FDA EventsGilead Sciences FDA EventsGalmed Pharmaceuticals FDA EventsKaryopharm Therapeutics FDA EventsKura Oncology FDA EventsLantern Pharma FDA EventsQuoin Pharmaceuticals FDA EventsRezolute FDA EventsScienture FDA EventsVera Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Delcath Systems FDA Events ClearPoint Neuro FDA Events Sight Sciences FDA Events Profound Medical FDA Events Orchestra BioMed FDA Events Sanara MedTech FDA Events KORU Medical Systems FDA Events Treace Medical Concepts FDA Events Apyx Medical FDA Events Nano-X Imaging FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:NYXH last updated on 8/11/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersThe Rare Earth Shift Few Saw ComingRare earth elements sit inside modern defense systems, high-performance magnets, and advanced electronics - ye...i2i Marketing Group, LLC | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredA gold storm is coming – are you ready?The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following s...Traders Agency | SponsoredOne coin wired into Elon's visionIt happened with Tesla. With Dogecoin. Each time, the same pattern. Every time the world buys into Elon's ...Crypto 101 Media | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIf You Have $50k+ on Coinbase, This Will Ruin Your DayOctober 14th, 2025, CNBC quietly published an interview with BlackRock's CEO, who went on live television and ...Decentralized Masters | SponsoredOver 90 Years Later, Trump May Finally Reverse 1933's Gold HeistTucked inside U.S. Code Title 31, Section 5117 is a provision allowing the Treasury to reprice America's gold ...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nyxoah SA Please log in to your account or sign up in order to add this asset to your watchlist. Share Nyxoah With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA approved - August 8,2025Fda Approved Drug: GenioAnnounced Date: August 8, 2025Indication: For the Treatment of Obstructive Sleep ApneaAnnouncementNyxoah SA announced that the U.S. Food and Drug Administration (FDA) has approved the Genio system for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65.AI SummaryNyxoah SA announced that the U.S. Food and Drug Administration has approved the Genio system for treating obstructive sleep apnea in patients with an Apnea-Hypopnea Index (AHI) between 15 and 65. Genio uses bilateral hypoglossal nerve stimulation with a leadless implant, a non-implanted battery solution, and a full-body 1.5T/3T MRI-compatible wearable controller. The wearable component powers, controls, and can be fully upgraded for software and battery without surgery. In the DREAM pivotal trial, Genio met key safety and efficacy endpoints. It achieved a 63.5% AHI responder rate, a 71.3% oxygen desaturation responder rate, and a 70.8% median AHI reduction. Moreover, 82% of participants lowered their AHI to below 15. Genio proved effective in all sleeping positions, cutting AHI by 66.6% when patients lay on their back and by 71% in other positions. Olivier Taelman, Nyxoah’s CEO, said this approval marks a milestone in bringing innovative, simple sleep therapy to U.S. patients with moderate to severe OSA.Read Announcement
